Navigation Links
Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
Date:9/21/2007

RALEIGH, N.C., Sept. 21 /PRNewswire/ -- Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industries, today announced that Ben Bonifant, Vice President and head of Campbell's Business Development practice, will moderate a panel discussion at the Pharmaceutical Strategic Alliances (PSA) conference hosted by Windhover Information. The conference will be held September 25-27, 2007 at The Marriott Financial Center in New York City.

The panel discussion, titled "Comparing the Long-Term Optimism of Platform Technologies to the Immediate Market Opportunities of Late-Stage Products," will explore whether a new technology needs to be demonstrated through the advancement of a late-stage product before a potential suitor is willing to discuss a deal. Scheduled for September 25 at 4:30 p.m., the panel will include participation from four senior-level industry executives with experience negotiating both platform technology and late-stage product deals. Mr. Bonifant will open the panel with a brief analysis of deal trends over the past 10 years involving platform technologies and late-stage products, as well as those deals that eventually advanced to an outright acquisition of the out- licensing company. The panel will then move into an interactive question and answer session.

"Over the past 10 years it has been interesting to watch the licensing environment for pharma and biotech products move from one that was very much in favor of licensing early-stage platform technologies to one that found the need wait until a technology was proven through the advancement of a derived compound to phase 2 or phase 3 of development," stated Bonifant. "In the past 18 months we've seen a resurgence of interest in platforms, with several development deals coming to fruition. Some notable deals even started as previous single-product relationships surrounding an innovative technology and resulted in outright acquisitions just recently. Clearly, a factor driving the acquisition of several platform companies has been the recognition within large pharma companies of a need to build out their biologics capabilities," he continued.

Mr. Bonifant has been a management consultant for nearly 15 years, helping leaders of global pharmaceuticals and biotechnology organizations and decision makers in large private equity funds. His perspectives on developments in the life sciences market are frequently published in industry and strategy journals, and he is a frequent guest lecturer at some of the nation's premier universities. Mr. Bonifant earned an MBA from the Stanford Graduate School of Business.

For more information on Windhover's Pharmaceutical Strategic Alliances conference, please visit http://www.windhover.com/psa.

About the Business Development Practice at Campbell Alliance

The Business Development Practice at Campbell Alliance helps licensing executives achieve an edge over the competition. Our consultants provide experienced counsel to clients who need assistance developing business development strategies, identifying partners, prioritizing targets, evaluating opportunities, and negotiating deals.

The firm's team includes seasoned consultants and industry professionals in pharmaceutical and biotech business development who have identified, assessed, and executed numerous in-licensing deals. They have also been valuable in aiding out-licensors, helping clients improve internal processes for pharmaceutical business development, and assisting top executives chart new strategies in corporate development.

About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industries. The firm's clients include most of the world's top 20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function, including Brand Management, Business Development, Clinical Development, Managed Markets, and Sales. From its locations in Raleigh, N.C., Parsippany, N.J., Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, and Atlanta, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.

CONTACT:

James Forte

Director, Public and Media Relations

Campbell Alliance

919-844-7100, extension 7195

jforte@campbellalliance.com


'/>"/>
SOURCE Campbell Alliance
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Biomedical Alliance about more than stem cells
2. Doyle seeks $2.5M for biomedical alliance
3. Alliance looks to create the right chemistry in SE Wisconsin
4. Biomedical alliance marks first full year
5. New alliance to provide Wi-Fi network for City of Madison
6. Budget axe could cut SE Wisconsin tech alliance funding
7. Biotech Alliance pushes ahead in SE Wisconsin with likely state funding
8. Milwaukee research alliance sees need for incubator
9. University alliance gets $2.5 million to encourage minorities in science and technology
10. Suite Scheduler Announces Alliance with Ice Technologies
11. Alliance Brings E-Business Technologies to Wisconsin Manufacturers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):